Syncom Formulations (India) Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Net profit of Syncom Formulations (India) rose 42.28% to Rs 25.17 crore in the quarter ended March 2026 as against Rs 17.69 crore during the previous quarter ended March 2025. Sales declined 9.05% to Rs 135.41 crore in the quarter ended March 2026 as against Rs 148.88 crore during the previous quarter ended March 2025.

For the full year,net profit rose 54.64% to Rs 76.44 crore in the year ended March 2026 as against Rs 49.43 crore during the previous year ended March 2025. Sales rose 5.20% to Rs 489.17 crore in the year ended March 2026 as against Rs 465.01 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Net profit of Syncom Formulations (India) rose 40.40% to Rs 24.57 crore in the quarter ended March 2026 as against Rs 17.50 crore during the previous quarter ended March 2025. Sales declined 9.74% to Rs 134.00 crore in the quarter ended March 2026 as against Rs 148.46 crore during the previous quarter ended March 2025.

For the full year,net profit rose 55.54% to Rs 76.01 crore in the year ended March 2026 as against Rs 48.87 crore during the previous year ended March 2025. Sales rose 5.12% to Rs 486.57 crore in the year ended March 2026 as against Rs 462.85 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Net profit of Syncom Formulations (India) rose 45.46% to Rs 18.91 crore in the quarter ended December 2025 as against Rs 13.00 crore during the previous quarter ended December 2024. Sales declined 9.72% to Rs 115.14 crore in the quarter ended December 2025 as against Rs 127.53 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News